Eli Lilly Shares Jump 6.4% After UK Clears Foundayo GLP-1 Pill
Updated
Updated · Yahoo Finance · Aug 22
Eli Lilly Shares Jump 6.4% After UK Clears Foundayo GLP-1 Pill
3 articles · Updated · Yahoo Finance · Aug 22
Summary
Eli Lilly rose 6.4% after the UK approved Foundayo, a once-daily oral GLP-1 for weight management and type 2 diabetes, giving the drugmaker a new near-term growth lever beyond its injectable blockbusters.
Foundayo's clearance landed alongside strong Mounjaro and Zepbound-driven revenue growth, a higher full-year outlook and progress in Lilly's next-generation GLP-1 pipeline, reinforcing investor confidence in its obesity and diabetes franchise.
The approval also starts to test whether orforglipron can gain traction as an oral alternative, potentially easing single-product concentration risk while deepening Lilly's dependence on GLP-1 demand and reimbursement decisions.
Lilly's longer-term case still hinges on sustaining premium growth: one baseline narrative points to $118.0 billion in 2029 revenue and $48.7 billion in earnings, while payer and formulary pushback remains the main risk.
Could Lilly's highly anticipated daily pill make weight-loss injections obsolete, or will it unexpectedly cannibalize their own multi-billion-dollar profits?
With counterfeit weight-loss drugs flooding the market, can this convenient new oral pill finally crush the dangerous underground economy for GLP-1s?
As Lilly tests its obesity pill for sleep apnea and arthritis, is the world ready for a single daily pill that treats everything?